To compare the impact on tumor eradication of HER2-specific CAR NK cells as living drugs with the effect of NK cells targeted by passively diffusing trastuzumab, we generated human CAR NK-92 cell lines that stably express second and third-generation HER2-specific CARs. Here, ERBB2 is linked to neoplasm.